Synapse - Phase II study of pharmacokinetic model-based ATG dosing to improve survival through enhanced immune reconstitution in patients undergoing ex vivo CD34-selected allogeneic HCT (PRAISE-IR)

Phase II study of pharmacokinetic model-based ATG dosing to improve survival through enhanced immune reconstitution in patients undergoing ex vivo CD34-selected allogeneic HCT (PRAISE-IR) Meeting Abstract

Authors:	Scordo, M.; Perales, M. A.; Mauguen, A.; Lin, A.; Kunvarjee, B.; Bieler, J.; Nguyen, L. K.; Paes Pena, M.; Cho, C.; Gyurkocza, B.; Harris, A. C.; Jakubowski, A. A.; Lin, R. J.; Papadopoulos, E. B.; Politikos, I.; Ponce, D. M.; Shaffer, B. C.; Shah, G. L.; Spitzer, B.; Tamari, R.; Giralt, S. A.; Boelens, J. J.; Curran, K. J.
Abstract Title:	Phase II study of pharmacokinetic model-based ATG dosing to improve survival through enhanced immune reconstitution in patients undergoing ex vivo CD34-selected allogeneic HCT (PRAISE-IR)
Meeting Title:	50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Journal Title:	Bone Marrow Transplantation
Volume:	59
Issue:	Suppl. 1
Meeting Dates:	2024 Apr 14-17
Meeting Location:	Glasgow, Scotland
ISSN:	0268-3369
Publisher:	Nature Publishing Group
Date Published:	2024-10-01
Start Page:	56
End Page:	58
Language:	English
ACCESSION:	WOS:001365375000058
PROVIDER:	wos
DOI:	10.1038/s41409-024-02347-7
Notes:	Meeting Abstract: O056 -- Hybrid Meeting -- Source: Wos